Botanical extract from vietnamese plant tested for safety in first human trial

NCT ID NCT07300202

Completed Knowledge-focused Sponsor: Oriplantee Company Limited Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This early-stage study tested the safety of a single dose of Orialpha (BD-C), a drug made from the Uvaria grandiflora plant, in 15 healthy adults aged 18 to 60. Researchers monitored side effects and determined the highest safe dose. The study does not test whether the drug works against breast cancer, but it is a first step toward future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Orialpha (BD-C), a botanical extract from the Uvaria grandiflora plant
What this could lead to: If safe, this could pave the way for future studies testing Orialpha as a potential treatment for breast cancer.
What could go wrong: This is a very early Phase I safety study in only 15 healthy people. It does not test whether the drug works against cancer, and many early-stage drugs fail to show benefit later.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER EVALUATE THE SAFETY PROFILE AND TOLERABILITY OF ORIALPHA IN HEALTHY ADULT VOLUNTEERS

Botanical extract from vietnamese plant tested for safety in first human trial

Summary

What this could mean

Get notified about this study

Conditions

As listed by the trial registrant

Contacts and locations

Locations

More trials for these conditions